All In Biotech

Drug Trial Radar · NCT07587099

Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)

An Investigator-initiated, Multicenter, Open-label, Randomized Controlled Non-inferiority Trial to Assess the Single vs. Dual Antiplatelet Therapy in the Chronic Coronary Syndrome (CCS) and Stable Acute Coronary Syndrome (S-ACS) Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (DCB)-Only Strategy (KONG-FREEDOM-I)

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,170 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,170

Planned (sponsor's estimate)

Start

May 4, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Gan LijunAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This investigator-initiated, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) utilizing a P2Y12 inhibitor compared to dual antiplatelet therapy (DAPT) in the chronic coronary syndrome (CCS) and stable Acute Coronary Syndrome (S-ACS) patients undergoing percutaneous coronary intervention (PCI) with the latest generation rapamycin drug-coated balloon (DCB) without stent implantation. The study aims to assess rates of ischemic and bleeding adverse events.

Conditions

  • Coronary Heart Disease (CHD)

Interventions

  • Drug-coated balloonDevice

    Fireliums rapamycin eluting coronary balloon dilatation catheter is a rapid exchange catheter, it has a patented microcrystalline coating process to ensure rapid drug delivery to the blood vessel wall and achieve a long-lasting sustained release effect, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.

  • Single antiplatelet therapy (SAPT)Drug

    The antithrombotic regimen is single antiplatelet (P2Y12 inhibitor)therapy (SAPT). The Investigator will decide whether to use ticagrelor first; if ticagrelor is not the first-line recommended drug, then clopidogrel will be considered. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.

  • Dual antiplatelet therapy (DAPT)Drug

    The antithrombotic regimen will follow the standard of care with a dual antiplatelet regimen (DAPT) per local preferences and international guidelines/ARC consensus paper. The type of agent and treatment duration will be selected according to the patient's clinical characteristics.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Net Adverse Clinical Events (NACE) at 12 months after randomizationTime frame: 12 months after randomization

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Luhe Hospital Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China · Not yet recruiting

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Not yet recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Heze Municipal Hospital

    Heze, Shandong, China · Not yet recruiting

  • Shandong Provincial Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Shandong Provincial Third Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, China · Recruiting

  • Liaocheng People's Hospital

    Liaocheng, Shandong, China · Not yet recruiting

  • Qingdao Municipal Hospital

    Qingdao, Shandong, China · Not yet recruiting

  • Tai'an City Central Hospital

    Tai’an, Shandong, China · Not yet recruiting

  • Zaozhuang Municipal Hospital

    Zaozhuang, Shandong, China · Not yet recruiting

  • Shanghai Fengxian District People's Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.